Resources

Pricing Execution Excellence

While C-Level executives have huge ambitions in innovating pricing, firms are faced with barriers on their way to implementation. Consider the executives participating in Accenture’s global pricing study. Nearly all (94 percent) see pricing as one of their main strategic priorities. However, only one-third said their company has implemented new pricing approaches widely across the organization. This suggests many companies still aren’t achieving their pricing goals — and that points to shortcomings in implementation and execution.

Lena Chatchatrian

Resources

Pricing for Survival or Pricing for Success?

New market realities are leading many businesses to the realization that spreadsheets and ERP systems are just not built to handle the levels of pricing performance, scalability, and even complexity needed to accommodate pricing for the modern B2B buyers. This eBook will help you understand the importance of shedding traditional methods of managing price by highlighting 7 key considerations. You'll learn why technologically advanced pricing capabilities will allow you to gain enhanced understanding and control of your dynamic price strategies, so you can succeed in today’s digital commerce marketplace.

Lena Chatchatrian

Resources

BMS, Roche, AZ Lose Out as China Favors Domestic Companies in 2020 NRDL PD-1 Battle

In the days before 2020 came to a close, China’s National Healthcare Security Administration (NHSA) and Ministry of Human Resources and Social Security (MOHRSS) issued the 2020 Edition of the National Reimbursement Drug List (NRDL).

This year, PD-1 inhibitors — a category of drugs that are often costly yet highly effective — were the hot issue between multinational corporations (MNCs) and domestic businesses. When the negotiations came to a close, home-grown PD-1 efforts from Shanghai Junshi Biosciences, BeiGene Ltd. and Jiangsu Hengrui Medicine took the coveted spots from household names like Roche, Bristol Myers Squibb, AstraZeneca and MSD.

Lena Chatchatrian

Resources

The Pricing Revolution

C-level executives continue to consider pricing a top strategic priority, and for good reason: It’s the largest driver of growth in customers, revenue, and profits.

New global research from Accenture highlights the current state of pricing as well as where pricing is headed in the near future. They surveyed more than 500 C-level executives in companies with more than US$1 billion in revenue across 17 business-to-business (B2B) and business-to-consumer (B2C) industries in Europe, Asia, and America.

Lena Chatchatrian

Resources

Dynamic Pricing

C-level executives continue to consider pricing a top strategic priority, and for good reason: It’s the largest driver of growth in customers, revenue, and profits.

In the “old days,” pricing used to be largely a “set it and forget it” exercise. But not anymore. Automated price setting and more frequent price changes to best capture customers’ willingness-to-pay is today’s “holy grail” of pricing for most companies. Pioneered by airlines’ smart revenue management systems, dynamic pricing has gained prominence in many other settings — including hotels, ride hailing, e-commerce and, increasingly, traditional retail. 

Lena Chatchatrian

Resources

New Price Models

C-level executives continue to consider pricing a top strategic priority, and for good reason: It’s the largest driver of growth in customers, revenue, and profits.

What’s helped some of today’s most successful companies flourish? A big factor is their pairing of innovative digital offerings with new price models that are fast becoming the focus in every industry B2C and B2B companies,especially some of the most successfulcompanies in media and technology.

Lena Chatchatrian

Resources

How Does the Biden Administration Want to ‘Take on Pharma?’

  • Democratic President-elect Joe Biden and his administration are poised to take the reins from President Donald Trump, who had just begun to more stringently address prescription drug prices in the U.S. via Executive Orders (EOs) aimed at introducing an American version of reference pricing.
  • Throughout his campaign, Biden has promised to expand access to health care through the “BidenPlan,” an evolution of former President Barack Obama’s Affordable Care Act, dubbed “Obamacare,”while “taking on big pharma” and reining in “runaway” drug prices.
  • Biden has also announced intentions to set up a government-run, Institute for Clinical and Economic Review (ICER) -style Health Technology Assessment (HTA) body, as ICER is currently an autonomous body to the U.S. government

Lena Chatchatrian